Actively Recruiting

Age: 18Years +
All Genders
NCT05846581

Registry of GORE® ACUSEAL Vascular Graft in Dialysis Access

Led by W.L.Gore & Associates · Updated on 2025-07-09

72

Participants Needed

5

Research Sites

197 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The goal of this observational study is to evaluate safety and performance of GORE® ACUSEAL Vascular Graft for the treatment of CKD in patients with ESRD in hemodialysis. The main questions it aims to answer are: * Safety: Freedom from device-related infection adverse events at 24 months from device implant * Performance: Secondary patency at 24 months from device implant. Participants, after informed consent is obtained, will be implanted with GORE® ACUSEAL Vascular Graft and followed for 24 months in standard of care, to evaluate safety and performance of the device.

CONDITIONS

Official Title

Registry of GORE® ACUSEAL Vascular Graft in Dialysis Access

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patient requires vascular access creation for hemodialysis due to End-Stage Renal Disease and plans to use GORE4 ACUSEAL Vascular Graft for arteriovenous access
  • Age 18 years or older at time of informed consent
  • Willing to follow institutional standard care for follow-up
  • Signed informed consent form
  • Currently on hemodialysis or expected to start hemodialysis within 30 days after graft placement
  • Expected to remain on hemodialysis for at least 12 months
Not Eligible

You will not qualify if you...

  • Known or suspected systemic infection
  • Pregnant or breastfeeding
  • Had vascular surgery or intervention on the study limb within 30 days before graft placement
  • Previously had unsuccessfully treated central venous stenosis on the same side
  • Taking maintenance corticosteroids or immunosuppressants such as rapamycin, mycophenolate, prednisone over 10 mg, cyclosporine, tacrolimus, or cyclophosphamide
  • Known blood clotting or bleeding disorder
  • History of Heparin Induced Thrombocytopenia type 2 or sensitivity to Heparin
  • Currently enrolled in another investigational study
  • Previously enrolled in this registry
  • Being considered for a live donor kidney transplant
  • Life expectancy less than 2 years

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 5 locations

1

Evangelisches Klinikum Bethel (EvKB)

Bielefeld, Germany, 33611

Actively Recruiting

2

Ev. DiakonissenKrankenhaus Leipzigemeinnützige

Leipzig, Germany, 04177

Actively Recruiting

3

ASST-Settelaghi Ospedale di Circolo e Fondazione Macchi

Varese, Italy, 21100

Actively Recruiting

4

North Bristol NHS Trust Southmead Hospital

Bristol, England, United Kingdom, BS10 5NB

Actively Recruiting

5

King's College Hospital NHS Foundation Trust

London, England, United Kingdom, SE5 9RS

Not Yet Recruiting

Loading map...

Research Team

E

Elisabetta Ferro

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here